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Antioxidant nanoparticles have gained recently tremendous attention for their enormous 
potential in biomedicine. However, discrepant reports of either medical benefits or toxicity, 
and lack of reproducibility of many studies, generate uncertainties delaying their effective 
implementation. In this review, we consider the case of cerium oxide, a well-known catalyst 
in the petrochemistry industry and one of the first antioxidant nanoparticle proposed for 
medicine. Like other nanoparticles, it is now described as a promising therapeutic alternative, 
now as threatening to health. Sources of these discrepancies and how this analysis helps to 
overcome contradictions found for other nanoparticles are summarized and discussed. For the 
context of this analysis, we review what has been reported in the liver, where many diseases 
are related to oxidative stress. Since well-dispersed nanoparticles passively accumulate in 
liver, it represents a major testing field for the study of new nanomedicines and their clinical 
translation. Even more, many contradictory works have reported in liver either cerium oxide 
associated toxicity or protection against oxidative stress and inflammation. Based on this, 
finally, the intention is to propose solutions to design improved nanoparticles that will work 







The last three decades have witnessed the emergence of nanotechnology as a “disruptive 
technology”, with great potential to contribute to improved treatments by the generation of 
new diagnostic and therapeutic products. In particular, inorganic nanoparticles (NPs) have 
emerged as flexible platforms to develop new imaging and therapy agents for detecting and 
treating diseases at its earliest stages, with benefits superior to any currently used 
treatments.[1] These materials have been reported as robust drug carriers, versatile scaffolds 
able to adjust conjugated biomolecules activity and antennas that can be excited in 
biologically transparent media.[2] Besides, they can be easily detected and tracked in 
physiological environments due to their unique physicochemical signatures.[3] Thus, 
nowadays, with the requirements for more personalized treatments and precision 
medications,[4] the interest in these materials to develop multimodal/multifunctional nanosized 
particles that can perform diagnosis[5] and different therapies (such as chemo-, thermo-, 
radio-, immuno- therapies) in a single nanoplatform[6] is continuously growing.[7] 
 
Amongst the broad range of newly proposed nanomaterials, antioxidant NPs add to this list of 
advantages that they even show therapeutic action by themselves.[8] Back in 2004, Manea et 
al. introduced the concept of nanozymes to describe the RNase-like behavior of AuNPs used 
as catalysts for the cleavage of phosphate esters.[9] From this, nowadays the vast majority of 
NPs intended for medical applications are inorganic metal (e.g. AuNPs) and metal oxides (e.g. 
CeO2,
[10]   TiO2,
[11] Fe3O4,
[12] and MnO2
[13]).  Recently, metal-free NPs (mainly black-
phosphorous nanosheets) have been also reported.[14] Those inorganic NPs can be powerful 
antioxidant and anti-inflammatory agents[15] and they can initiate biological responses to 
enable different therapies such as photodynamic therapy,[11, 13] chemodynamic therapy[16] and 
sonodynamic therapy,[17] among others. In addition, they can modulate biological 




for improving cancer therapy.[19] All this has opened the way for what has been called 
“nanocatalytic medicine”,[20] or “antioxidant nanomedicine”.[21] 
 
The recent works of Liu et al.[22] on “antioxidant nanomaterials” and Wang et al.[23] and 
Ghorbani et al.[24] on “nanozymes” offers a comprehensive review of different types of NPs 
proposed in the scientific literature. Furthermore, the rationale behind their important role of 
NPs in nanomedicine, the new developments in this promising therapeutic strategy, and the 
mechanisms of action of antioxidant nanosystems have been also recently described and 
reviewed.[20b, 21] Similarly, recent advances in specific enzymatic activities of different 
nanomaterials have been reviewed such as glucose oxidase[25] and peroxidase activities.[26] 
 
However, and as it happens with other new materials, despite their biomedical potential, little 
progress is achieved towards translation to clinical practice due to economic, societal and 
technical aspects. Amongst the latter, plenty of discrepant reports, either showing NPs as 
promising therapeutic alternatives in medicine or as threatening to health, are still fueling the 
debate of their safe use.[27] As an example, the same year two different reviews appear 
pointing out the beneficial[10] and the adverse[28] medical effects of CeO2NPs. In addition, 
their evolution in physiological environments and their potential toxicity and fate in the long-
term are not completely understood.  
 
As a consequence, only very few NPs -few iron oxides- have been approved by regulatory 
agencies, and only for applications such as iron replacement therapy for the treatment of 
anemia or as contrast agent for magnetic resonance imaging.[29] In this context, herein, we aim 
to review first the paradigmatic case of the reactivity of antioxidant cerium oxide NPs 
(CeO2NPs) in the liver (section 3). Learnings from this case can be extended to other NPs, 




enable the use of NPs in medicine (sections 4 and 5). CeO2 is selected here as a representative 
antioxidant NP in medical applications. Being a widely known and used catalyst in the 
petrochemical industry, it was one of the first NP proposed to be used as a therapeutic 
agent.[30] Currently, a large number of reports praise its wide spectrum enzyme-mimetic 
activities and immunomodulatory properties that protect tissues against reactive oxygen 
species (ROS) overproduction and inflammation (Figure 1A). Hence, CeO2NPs have been 
shown to modulate oxidative stress in diseases such as retinal degeneration,[31] neurological 
disorders,[32] ischemia,[33] cardiopathies,[34] diabetes,[35] gastrointestinal inflammation,[36] liver 
diseases[37] and cancer[38], as well as in regenerative medicine[39] and tissue engineering.[40] 
Even more, CeO2NPs was the first material tested as antioxidant NP in the space. In 2017, a 
team of the European Space Agency flown with CeO2NPs and proved that the particles 
remained stable and provided protection to the muscle cells.[41] In 2019, another experiment 
started in the International Space Station to test the CeO2NPs activity under conditions of 








Figure 1. Different reactions and applications in which CeO2NPs are being proposed or used as 
antioxidant NPs. A) In nanomedicine research. References are, to the best of our knowledge, the first 
study reporting the application. We apologize in advance if other contributions were before the ones 
here listed. Abbreviations: SOD: M=Cu (n=1); Mn (n=2); Fe(n=2); and Ni (n=2); Catalase: Fe(III)-E 
(heme group iron center attached to catalase; Fe(IV)-E•+  (mesomeric form of Fe(V)-E, i.e.,iron not 
completely oxidized to +V); Peroxidase: The electron donor is very dependent on the structure of the 
peroxidase. They also may contain in their active site, among others, a heme cofactor or redox-active 
cysteine or selenocysteine residues. B) In three ways catalytic converters, where I. Oxidation of unburnt 
hydrocarbons; II. Oxidation of Carbon Monoxide (CO); III. Reduction of Nitrogen Oxides to Nitrogen; 
C) In water shift reactions and D) Other applications where CeO2NPs are used. 
 
Along with these interesting applications, the focus on the effects in the liver is a logical 
approach. First, because it is the organ where the majority of the administered nanomaterials 
passively accumulate. Thus, it represents a major testing field to start the studies of the NPs 
evolution, pharmacokinetics, and activity,[42] and consequently, enable the clinical translation 
of newly developed nanomedicines. Second, the liver is where many discrepant reports show 
protective effects of CeO2NPs against ROS overproduction and inflammatory processes or the 
opposite, a role in promoting oxidative stress and toxicity (section 3).  These contradictions 




5).  Thus, it is reasonable to anticipate that knowledge gain in the liver will pave the way for 
NPs applications (and other NPs in general) in other organs and tissues once targeted 
therapies will be a widespread reality. 
 
2. CeO2NPs in biomedicine: A historical perspective 
 
The ability of CeO2NPs to balance redox homeostasis in pathological conditions makes it one 
of the most promising materials to develop new treatments for many diseases. Despite the 
catalytic capacities of CeO2 are known since long, its powerful medical potential has been 
evaluated only during the last years, after the pioneering observations of Professor Beverly 
Rzigalinski and co-workers.[30, 43] Back in 2003, Prof. Rzigalinski and her Ph.D. student David 
Bailey, at the Virginia State University, unexpectedly observed that CeO2NPs of less than 20 
nm prolonged the lifespan of brain cell cultures, for periods of up to 6-8 months.[30c] This 
finding was described by Prof. Rzigalinski as “somewhat serendipitous” since they were 
carrying out research using CeO2NPs as a drug carrier.
[44] 
 
Thus, the discovery of the pharmacological potential of CeO2NPs is a recent event. It 
occurred just at the beginning of this century. But, of course, “an unprepared time cannot see 
the outstretched hand of opportunity”. This discovery benefited from a long sequence of 
previous research efforts and results that provided the framework for considering its 
importance and enabling its continuation as a subject of research (Figure 2). The rare earth 
(the fifteen lanthanides (Ln), as well as scandium and yttrium) have been found to have 
biomedical applications since the XIX century. The first one was the use of Cerium Oxalate 
as antiemetic, of particular use in the sickness that accompanies pregnancy.[45] Subsequently, 
it came to be prescribed for other gastrointestinal disorders and even for coughs. With the 




the possibilities arising from their ionic radii similar to calcium ions (Ca2+) but with higher 
charge.[46] Ln3+ ions were found to have a high affinity for Ca2+ sites on biological molecules 
and rapidly were applied in lowering blood pressure, serum cholesterol and glucose levels, in 











It was for this anticoagulant role, and following the hypothesis that blood coagulation and 
inflammation were closely linked processes, that Prof. N. Jancsó introduced the potential anti-
inflammatory properties of a variety of Ln.[48] In experiments of late 1950’s and early 1960’s, 
he proved in rats that rare earth metals such as La3+, Ce3+, Nd3+, Pr3+, and Sm3+ were 
effective, even in the form of their inorganic salts, in inhibiting the angiotaxis and edema that 
follows the increase in vascular permeability caused by inflammatory agents such as bee 
venom, cobra venom or dextran.[48] These anti-inflammatory properties were replicated 
afterward.[49] However, due to excessive toxicity of the Ln salts used (nitrates and chlorides), 
and the unknown mechanism, Ln did not fulfill their early promise as medically useful anti-
inflammatory agents until the recent advent of CeO2 in its nanoparticulate form. 
 
Nevertheless, beyond therapy, several Ln, and particularly Ce, found a successful biomedical 
use as contrast agents to image specific organs and tissues. A variety of light and electron 
microscopical histochemistry methods have been developed with the aid of cerium 
preparations.[50] Again, the bulk of this work has been done with cerium nitrates and 
chlorides. Briggs et al.[51] introduced the use of cerium chloride for the detection of Hydrogen 
Peroxide (H2O2) production to determine the ultrastructural localization of NADH oxidase. 
This protein was being studied at that time as an enzyme possibly involved in the increased 
oxidative activity of polymorphonuclear leukocytes (PMN) during phagocytosis. Since then, 
Ce3+, for its electron density and its ability to capture H2O2 as product of oxidase activity has 
been profusely used in different techniques using light and electron microscopies for the in-
situ detection of the activity of many other oxidases[52] and phosphatases.[53] In these methods, 
the final reaction products are fine insoluble Ce4+-containing precipitates, Ce perhydroxides 
or Ce phosphates, some in the form of unintended spontaneous NPs, that enable a very precise 




advances have been made in cell biology, such as the explanation of extracellular ATPases 
function and the discovery of new organelles.[50] 
 
In this context, and for this historical perspective, it is worth highlighting the work of Telek et 
al. in 1999.[54] These authors used a Ce based technique for the in vivo histological detection 
of oxygen-derived free radicals in inflammatory conditions, by quantifying cerium reflectance 
signals in PMNs. They showed that using DPI (diphenylene-iodonium chloride, a NADPH 
oxidase inhibitor), SOD (superoxide dismutase) and catalase, the formation of reflectant 
precipitates around PMNs decreased, confirming their inhibitory action on oxidative stress. 
However, they observed that SOD also reduced the formation of cerium precipitates. They 
discussed that one may expect SOD to increase these precipitates since SOD catalyzes the 
dismutation of superoxide anions to H2O2 and is H2O2 which produces the Ce-perhydroxide 
precipitate. But the opposite was observed. Although potential mechanisms of interactions of 
Ce with those enzymes were not elucidated, this report hinted a possible role of Ce 
precipitates in the decrease of the free radical species.  
 
Interestingly, this study was concomitant with the huge rise in the popularity of antioxidants 
in the 1990s. The role of free radicals and antioxidants in biology was already known since 
the mid-XX century (see f.i. the works on aging and free radicals by Denham Harman,[55] 
Linus Pauling works -and philosophy- such as his book Vitamin C and the Common Cold[56] 
and the article published in 1971,[57] or orthomolecular medicine for everyone by A. Hoffer 
and A. W. Saul in 2008).[58] But it was in 1993 when antioxidants attracted attention 
worldwide as a consequence of a large human study (87,000 female nurses) published in the 
New England Journal of Medicine. The results of this study suggested that vitamin E 
supplements could be associated with a reduced risk of coronary heart disease in women.[59] 




inflammatory diseases, neurodegenerative diseases, and cancer, among others.[60] However, 
other studies pointed out the pitfalls of their use.[61] For instance, only one year after this 
work, another study showed that the supplementation with Vitamin E and Beta-Carotene did 
not prevent smoking-induced lung cancer. On the contrary, these supplements could have 
harmful effects.[62] This study had an 18-year postintervention follow-up with similar 
results.[63] In fact, since decades ago, it has been recurrently observed how promising 
preclinical studies of antioxidant therapies failed when translated to the clinic. This has been 
attributed to the non-druglikeness of available antioxidant compounds. These have high 
unspecific reactivity and limited absorption profiles, hence low bioavailability and low 
concentrations at the target site. In this context, radically new antioxidant substances like 
CeO2NPs, with their ROS buffering capacities and mild but permanent activity, may 
overcome previous limitations and enable antioxidant therapies to improve human health. 
This is discussed in more detail in section 4. 
 
 
In parallel to this, since early XX century,[64] another branch of science and technology 
developed a broad body of knowledge and applications resulting from the catalytic properties 
of CeO2.
[65] The first industrial application of CeO2 was in 1891, when Carl Auer von 
Welsbach, student of Robert Bunsen, incorporated it in incandescent mantles for lighting. 
When combined with other rare-earth metal oxides, cerium glows intensely as soon as it is 
warmed-up.[66] After this, CeO2 powders in micrometric and submicrometric sizes and more 
recently in controlled nanoparticulate sizes have been under intense scrutiny as structural and 
electronic promoters of catalytic reactions. In industry, CeO2 has been most widely used as an 
active component in processes such as three-way catalysts (TWC) for automobile exhaust-gas 




applications such as polishing agent for optical glasses and silicon wafers, grinding medium 
for computer parts and camera phone lenses). 
 
 
Although CeO2 industrial applications are beyond the scope of this review, it is worth to 
mention, in view to elucidate the mechanisms of CeO2NPs biological activity, the early 
investigation of CeO2 oxygen storage properties derived from its introduction in TWCs.
[67] 
The purpose of TWC is to promote the simultaneous oxidation of Carbon Monoxide (CO) and 
hydrocarbons and the reduction of Nitrogen Oxides (NOx). In such a way, the catalyst 
reduces both the fuel consumption and the emission of soot particles of combustion engines. 
A summary of the involved reactions is shown in Figure 1B-D. In TWC, the catalyst must be 
an oxygen buffering material, releasing oxygen in a reductive atmosphere and incorporating it 
by interacting with oxidizing gases present in the mixture, O2 many times. Thus, CeO2, and 
CeO2/ZrO2 mixtures, have been widely used as oxygen buffers. Since the 1970s−1980s, the 
preparation of TWC consisted essentially in the co-impregnation of noble metals, such as Pt, 
and CeO2 onto the Al2O3 support.
[68] During the mid-1980s, a second generation of CeO2-
containing TWCs was developed -with much higher performance- through the improvements 
in the material preparation to increase the CeO2 content and to optimize the dispersion of the 
CeO2 particles in the Al2O3 support.
[69] 
 
Therefore, in a context of pursuing antioxidant solutions to many diseases, the rising of 
studies of the catalytic applications of nanostructured CeO2 and the use of Ln and other NPs 
for biomedical research, it came the discovery that a cell culture of mixed brain cells 
incubated with CeO2NPs was still alive and actively signaling after a much longer period than 
their expected life span. A patent was presented[70] and three abstracts were published.[30] 




radicals can be applied to medicine, rapidly grew. Since then, many reports and studies are 
constantly appearing with promising results (Table 1). 
 
Table 1. Firsts and recent reports using CeO2NPs in different medical areas. 
 
Yeara) Area Description of the work 
2003 First use in 
nanomedicine 
CeO2NPs of less than 20 nm prolonged the lifespan of brain cell cultures, for periods 
of up to 6-8 months.[30] 
2005 Oncology Protection from radiation-induced damage: CRL8798 cells (immortalized normal 
human breast epithelial cell line) and MCF-7 (breast carcinoma cell line) were 
exposed to radiation. Further treatment with CeO2NPs was shown to confer 
radioprotection to the normal human breast line but not to the tumoral one.[38a]. 
Other, more recent, works can be found e.g. in Li et al.[38b] and Nourmohammadi et 
al.[38c]  
2006 Neurology CeO2NPs were found to be neuroprotective, limiting the amount of ROS that would 
decrease viability of nerve cells (HT22 hippocampal nerve cell line).[32a] 
Neuroprotective effect on adult rat spinal cord neurons demonstrated with 
electrophysiological recordings of retention of neuronal function in cultured cells 
isolated from rat spinal cords.[71] Other, more recent, works can be found e.g. in 
Kalashnikova et al.[32c] and Ranjbar et al.[32d] 
2006 Ophthalmology CeO2NPs prevented retinal degeneration induced by intracellular peroxides -and 
thus preserve retinal morphology and prevent loss of retinal function- in an in vitro 
primary cell culture of dissociated cells of the rat retina and an in vivo albino rat 
light-damage model injecting the suspension of CeO2NPs into the vitreous of both 
eyes.[31a] Other, more recent studies, can be found e.g. in the works of Cai et al.[31b, 
31c] 
2007 Cardiology Intravenously injected CeO2NPs in a transgenic murine model of cardiomyopathy 
reduced the myocardial oxidative stress, the endoplasmic reticulum stress and 




In vivo study show CeO2NPs potential to reduce ROS production in mice states of 
inflammation and hence proposed as a novel therapy for chronic inflammation.[15a] 
2011 Diabetes A combination of CeO2NPs and sodium selenium was beneficial to diabetic rats.
[35a] 
Another, more recent, work can be found e.g. in Khurana et al.[35b] 
2013 Hepatology CeO2NPs showed similar performance as N-acetyl cystine, a common therapeutic 
to reduce oxidative stress, in mice with induced liver toxicity (by CCl4).
[72] Other, 
more recent works can be found e.g. in Adebayo et al.[37b] and Fernandez-Varo et 
al.[37c] 
2014 Regenerative 
Medicine and tissue 
engineering 
The capacities of CeO2NPs to achieve functional restoration of tissue or cells 
damaged through disease, aging, or trauma through enhancing long-term cell 
survival, enabling cell migration and proliferation, and promoting stem cell 
differentiation were reviewed in the work of Das et al.[39] Another more recent work 
can be found e.g. in Marino et al.[40]  
2017-
2019 
NPs in the space CeO2NPs to counteract the detrimental effects of microgravity-induced oxidative 
stress.[41] 
a)To the best of our knowledge, we briefly describe here the firsts reports, and more recent ones, that 
apply the therapeutic potential of CeO2NPs in nanomedicine research. We apologize in advance if 
other contributions were before the ones here listed as the first one. 
 
3. Liver as a testing field for nanomedicine. The case of CeO2NPs 
The application of CeO2NPs in medicine is still a recent research area that needs more work 




understood and developed, a good starting point is what it is really known. When studying the 
safety, pharmacokinetics, and biodistribution of nanoparticulate materials in the body, it is 
already known that the liver and spleen are the major receptor sites after NPs administration 
(≈90 % of the dose administered), followed by the kidneys (≈9%) and other organs of the 
reticulum endothelial system, which act as NPs collectors.[73] Indeed, CeO2NPs are not an 
exception and plenty of studies confirm their passive accumulation in the liver. Hence, the 
liver represents a major testing field for the study of the pharmacokinetics and the therapeutic 
effects of CeO2NPs. Additionally, it is well-known the role of ROS in the genesis and 
progression of liver diseases such as non-alcoholic fatty liver disease (NAFLD) or 
hepatocellular carcinoma.[74] Therefore, the knowledge acquired here will also pave the way 
for further application of this and other NPs, and NPs in general, in other organs when 
properly targeted therapies will be developed.  
 
Thus, in this section, we aim to review different studies of CeO2NPs biodistribution, toxicity 
and therapeutic effects in different in vitro and in vivo experimental models of liver disease. 
The doses and types of CeO2NPs used (size, surface state, their source -either commercial or 
synthesized in the laboratory-, etc.) are also detailed for each report to better understand the 
results obtained. 
 
3.1. Biodistribution and final fate. Liver as passive target. Kuppfer cells or Hepatocytes? 
As said, there is a unanimous agreement that the liver and spleen are the major passive target 
of CeO2NPs. In an exhaustive biodistribution study, Yokel et al. administered high 
intravenous (i.v) doses of CeO2NPs (5, 15, 30 nm, 100 mg/kg; 55 nm, 50 mg/kg; all citrate 
capped) into Sprague Dawley rats and evaluated Ce biodistribution after 1 hour, 20 hours and 
30 days.[75] Again, liver and spleen contained a large percentage of the dose and there was no 




total dose of the 5 than 30 nm CeO2NPs at 20 hours, and the spleen contained significantly 
more of the 15 nm than the 5 nm ceria at 30 days, suggesting preferential accumulation of the 
smaller (5 nm) NPs by the liver and the larger (15 and 30 nm) by the spleen. In a similar 
study, these authors evaluated the biodistribution after 1h and 20 h of CeO2NPs (30 nm; 0, 50, 
250 or 750 mg/kg) following i.v. administration to Fisher 344 rats.[76] Results showed once 
more that the liver and spleen were the main targets and no major systemic injury was 
observed after 20 hours of a single dose of i.v. CeO2NPs infusion. In this work, a faster 
accumulation rate in the spleen at short times (first hours) and a decrease of Ce in the spleen 
correlated with an increase of Ce in the liver over time was observed. Intracellular CeO2 
agglomerations were observed in both Kupffer cells and hepatocytes. CeO2NPs produced a 
dose- and time-dependent increase of activated Kupffer cells, evident after 20 h at the 250 
mg/kg and 750 mg/kg doses.[76] Results from our groups after i.v. administration of albumin 
stabilized 4 nm CeO2NPs at 0.1 mg/kg of body weight (bw), twice a week during two weeks 
in control and fibrotic rats, showed most of the Ce detected in the liver (84% of the total dose 
of Ce collected).[37a] Furthermore, more than 75% of the initial Ce was still detected 8 weeks 
after administration. 
 
However, once accumulated in the liver, results in the literature are less coincident regarding 
the cell types, and subcellular localization, in which CeO2NPs are found. Hirst et al. carried 
out i.v. administration of CeO2NPs (3-5 nm) to C57BL/6 mice (single dose of 0.1 mg/kg or 
0.5 mg/kg) that were sacrificed after a week.[15a] Another mice group with an additional 
second dose (0.1 mg/kg or 0.5 mg/kg) administered at day 15 were sacrificed at day 30. In 
both cases, results showed that CeO2NPs were well tolerated. The presence of randomly 
scattered CeO2NPs within hepatocytes was observed using TEM images. Tseng et al. also 
evaluated biodistribution employing a high dose of CeO2 nanocubes (85 mg/kg, 30 nm, citrate 




1 hour after infusion, and ultrastructural analysis after 30 and 90 days revealed CeO2 
accumulations in Kupffer cells, stellate cells, and hepatocytes. In another study by the same 
group, a single i.v. injection of a high dose CeO2NPs (5 nm, citrate capped, 85 mg/kg) was 
given to Sprague Dawley rats and biodistribution was evaluated after 1 hour, 20 hours and 
720 hours (30 days).[78] Ce was initially observed in Kupffer cells with subsequent 
bioretention in parenchymal cells, hepatocytes, and hepatic stellate cells. A study from our 
groups showed that at subcellular level CeO2NPs were mainly located inside endosome-like 
bodies in human hepatocellular carcinoma (HepG2) cells.[79] In this work, CeO2NPs were also 
observed attached to the outer leaflet of the plasmatic membrane and free in the cytoplasm 
whereas mitochondria, endoplasmic reticulum, and the nucleus appeared normal. 
  
Results from other exposure routes than i.v. also show preferential accumulation in the liver 
although in less amount due to NPs retention at the portal entry. For instance, Modrzynska et 
al. evaluated Ce liver deposition after 1, 28 or 180 days of intratracheal instillation of 162 μg 
of CeO2NPs (79 nm) in C57BL/6 mice.
[80] Ce concentration increased over time and the 
translocation to the liver was 3% of the initial pulmonary dose after 180 days. Almost all the 
Ce detected beyond the airways was in the liver. Hirst et al. studied CeO2NPs (3-5 nm) 
administration to CD-1 mice perorally, i.v. or intraperitoneally (i.p.) (weekly for 2 or 5 weeks; 
0.5 mg/kg).[72] I.v. administration resulted in the greatest deposition, followed by i.p. and 
peroral. In both i.v. and i.p. administration, the liver, and the spleen had the highest 
concentration of CeO2NPs as measured per gram of tissue. Perorally administered mice had 
very few CeO2NPs deposition. In this study, no liver toxicity was observed regardless of the 
administration route. In another study, Molina et al., compared the bioavailability, tissue 
distribution, clearance and excretion of radioactive 141Ce after intratracheal instillation, 
gavage, or i.v. injection of neutron-activated 141CeO2NPs and 141CeCl3 in Wistar rats.
[81] As 




they were retained for at least 28 days. Orally administered CeO2NPs had low absorption 
from the gastrointestinal tract and rapid elimination through feces. Intratracheal administered 
CeO2NPs showed minimal extrapulmonary accumulation. Similarly, in the case of inhalation, 
exposure of Sprague Dawley rats to combustion-generated CeO2NPs (25 and 90 nm bimodal 
distribution), Ce was predominantly recovered in the lungs and feces, with extrapulmonary 
organs contributing less than 4 % to the recovery rate.[82] Recently, CeO2NPs uptake by ex-
vivo perfused human livers has been demonstrated by our groups.[37c] After administration, 
most of the CeO2NPs were readily accumulated in the liver and found both free and within 
intracellular single-membrane endosome-like organelles, while some were observed inside 
blood vessels, space of Disse and endothelial and blood circulating cells. 
 
Regarding the potential toxicity in the long-term and the final fate of NPs intended for 
medical applications, results and data are scarce. This could be most likely due to the cost of 
maintenance of the animal models and the limited possibilities of tracking nanomaterials over 
long periods of time.[83] Here, the use of CeO2NPs may benefit from the knowledge acquired 
with other colloidal inorganic NPs studied for longer times. For instance, Sadauskas et al.[84] 
in a study aiming to at revealing the fate of 40-nm AuNPs after intravenous injections found 
that the fraction of Kupffer cells containing AuNPs gradually decreased to about one fifth 
after 6 months and that at the end of the study only fewer macrophages accumulated AuNPs 
in growing clusters. However, there are fewer reports of the long term effects for the case of 
CeO2NPs, mainly addressing the effects of commercial CeO2NPs after inhalation exposure.
[85] 
One of the most comprehensive was a 2-year combined chronic toxicity developed at BASF 
SE (Ludwigshafen, Germany). Carcinogenicity studies were performed according to the 
Organisation for Economic Co-operation and Development (Test Guideline 453). In the 
course of this study, the effects of the CeO2NPs (40 nm) dosed at 0.1, 0.3, 1, and 3 mg/m³ 




assessed. Results showed that CeO2NPs did not elicit significant genotoxicity in the alkaline 
comet assay and micronucleus test.[86] However, CeO2NPs caused inflammatory and oxidative 
stress reactions in the respiratory tract by the release of inflammatory mediators, pointing out 
that signs for long-term effects still need to be further evaluated.[87] 
 
The low clearance rate in the liver is shown e.g. for AuNPs and it has been also reported in 
the case of CeO2NPs (see e.g the mentioned studies of Molina et al.
[81] and Modrzynska et 
al.[80]), while others have reported bioprocessing and/or dissolution and elimination without 
toxicity.[88] In this last case, routes of excretion of NPs from the body are feces and urine. In 
this context, it is important to mention that the degradation and dissolution of small NPs in 
biological environments is well described.[89] In the case of the liver, Muhammad et al. 
reported slow dissolution and biotransformation of CeO2NPs in physiological media.
[89d] It is 
also noteworthy that in the case of CeO2NPs recent studies suggest these modifications and 
evolution of CeO2NPs within the liver, indicating in vivo NP dissolution and bioprocessing. 
Graham et al. reported changes in the CeO2NPs within the liver 90 days after i.v. 
administration of CeO2 nanocubes (30 nm; 85 mg/kg/) into Sprague Dawley rats.
[90] 
Specifically, after 90 days of residence in the liver, a “second generation” of smaller 
CeO2NPs was observed, with higher redox activity. This study used a high amount of 
CeO2NPs, well above the usual therapeutic dose, but suggests that CeO2NPs may undergo in 
vivo processing inside the liver causing a shift toward smaller particle size and increased 
reactive surface area. In another study by the same authors, using advanced electron 
microscopy methods, CeO2NPs bioprocessing in the liver and spleen of Sprague Dawley rats 
receiving i.v. infusion of 85 mg/kg nanoceria (30 nm) was evaluated.[91] In agreement with 
previous observations, particles were also observed in the liver and spleen up to 90 days post-
infusion. Tissue granulomas were observed, mainly in the spleen but also in the liver, which 




doses. Note that these NPs were relatively large in size and with a considerable aggregation 
state, both slowing down dissolution. Furthermore, in the mentioned work of Modrzynska et 
al.[80] the observed NPs in the liver were found to decrease their sizes over time, possibly 
indicating NP degradation. 
 
3.2. CeO2NPs are not toxic in vitro and protect hepatic cells from induced cellular 
damage 
In vitro studies evaluating toxic or therapeutic effects have been performed in different cell 
types, including human cells. Again, doses used together with NPs characteristics are 
important when considering the biological effects. As in the in vivo case (section 3.3.), higher 
doses of CeO2NPs can compromise cell viability. For instance, Kitchin et al. evaluated the 
potential hepatotoxicity in human liver HepG2 cells of a 3-day exposure to two commercial 
CeO2 nanomaterials (8 nm and 58 nm) at 3 μg/ml or 30 μg/ml doses.
[92] It was observed an 
increase of <1.5-fold in 11 of 24 fatty acids when cells were treated with CeO2NPs at 3 μg/ml 
and around 2 fold increase in 20 of 24 fatty acids when cells were incubated with the same 
NPs at 30 μg/ml. In contrast, an increase of only one fatty acid (1.4-fold) was observed when 
cells were incubated with 58 nm CeO2NPs at 30 μg/ml. The same study observed a reduction 
in some glutathione and gamma-glutamyl metabolites when cells were treated with 8 nm and 
58 nm CeO2NPs at 30 μg/ml, although this was not observed when cells were treated with 8 
nm CeO2NPs at 3 μg/ml.
[92] Similar results were also observed by Kitchin et al. in another 
study with HepG2 cells exposed up 3 days to five different commercial CeO2 nanomaterials 
(30-100 μg/ml, sizes ranging from 15 to 213 nm).[93] Metabolomic assessment of exposed 






Doses higher than 50 µg/ml were found to induce cytotoxicity in other works. For instance, 
Cheng et al. using concentrations ranging from 0 to 200 µg/mL of hexahedral CeO2NPs (20–
30 nm) observed that concentrations higher than 50 μg/mL induced morphological damage, 
apoptosis and reduced viability in human hepatocellular carcinoma SMMC-7721 cells.[94] In 
these conditions, CeO2NPs increased the production of ROS and malondialdehyde (MDA), 
reduced the activity of SOD, GSH peroxidase and catalase and increased the phosphorylation 
levels of ERK1/2, JNK, and p38 MAPK. Another study showed that different concentrations 
and forms of CeO2NPs presented different toxicity on HepG2 cells.
[95] Specifically, the effects 
of three types of CeO2NPs with different morphologies (cube 20 -50 nm, octahedron 10-30 
nm and rod-like crystals 8nm x 100-400 nm) in HepG2 cells were compared at concentrations 
ranging from 6.25 to 100 μg/mL. Significant changes in cell morphology were observed from 
doses of 50 μg/mL and 100 μg/mL.[95] Experimental data obtained in our laboratories confirm 
these results. 
 
Conversely, under pathological stimuli, antioxidant activity and protective cellular effects of 
CeO2NPs have been observed in vitro on hepatic human cells, usually at doses lower than 100 
µg/ml. For instance, at 100 µg/ml of CeO2NPs (4nm), Oro et al. reported inhibition of 
intracellular ROS formation in HepG2 cells treated with H2O2.
[37a] Also, protective effects of 
CeO2NPs treatment (8.5 µg/ml) against hyperglycemic induced injury in HepG2 cells 
incubated in medium with 50 mM of glucose were described.[96] In these conditions, 
Shokrzadeh et al. showed that CeO2NPs decreased glucose-induced cytotoxicity, ROS 
production, and lipid peroxidation.[96] In another study, CeO2NPs used at concentrations as 
low as 1 ug/ml increased viability and decreased oxidative stress of RAW264.7 macrophages 
exposed to LPS.[97] A more recent work studied the effects of CeO2NPs in human hepatic 
cells WRL-68, a HeLa derivative cell line, after inhibition of catalase with 3-Amino-1,2,4-




100 uM (=17 ug/ml) or 150 uM (=25.5 ug/ml)) improved cell viability and decreased cellular 
ROS.[98] We have observed that CeO2NPs (10µg/ml; 4nm) reduced fatty acid content in 
human hepatic cells HepG2 cultivated under steatosis conditions.[79] Aiming for mechanisms 
to explain how CeO2NPs protect cells against oxidative stress, we performed 
phosphoproteomic analysis in those HepG2 cells. Results showed that CeO2NPs reverted the 
H2O2-mediated increase in the phosphorylation of peptides related to cellular proliferation, 
stress response, and gene transcription regulation, and interfered with H2O2 effects on mTOR, 
MAPK/ERK, CK2A1, and PKACA signaling pathways.[99]  
 
3.3. CeO2NPs are not toxic in vivo at therapeutic doses 
Liver toxicity of CeO2NPs in healthy rodents by different administration routes has been 
extensively evaluated and found to appear mostly when higher doses (tenths or hundreds of 
mg of CeO2 per Kg of animal) are used, recalling the Paracelsus toxicology maxim “sola 
dosis facit venenum” (the dose makes the poison). For example, in the mentioned study of 
Tseng et al.[78] single i.v. injection of a high dose CeO2NPs (5 nm, citrate capped, 85 mg/kg;) 
was administered into Sprague Dawley rats. Sustained CeO2 bioretention in the liver was 
associated with granuloma formations. A significant elevation of serum AST was seen at 1 
and 20 h, but not at 30 days after CeO2NPs administration, whereas apoptosis was observed at 
day 30.[78] These authors also observed adverse hepatic effects after the single i.v. infusion of 
the same mass concentration of CeO2 nanocubes (30 nm, citrate capped, 85 mg/kg) into 
Sprague Dawley rats. Small granulomas and an increase in apoptotic cell number were 
observed between days 30 and 90 after infusion. At these time points, fibrosis and necrosis 
were not observed and only small changes were found in ALT serum levels.[77]  
 
As discussed in section 4, another source of toxicity is NP aggregation. And NP concentration 




instillation of commercial CeO2NPs (20 nm; 1, 3.5 or 7 mg/kg) to Sprague-Dawley rats was 
associated with liver toxicity after 28 days.[100] Histopathological alterations observed 
included hydropic degeneration and enlargement of hepatocytes, dilatation of the sinusoids 
and nuclear enlargement. There was no evidence of granuloma, portal inflammation, fibrosis, 
or bile duct abnormalities, except for the presence of some local inflammation in the lobules 
of some animals. Increased serum ALT levels and reduced albumin levels were observed at 7 
mg/kg. The authors, though, describe how the NPs agglomerate into micrometric units when 
dispersed in the saline vehicle (NaCl 0.9%), which recalls the situation of frustrated 
phagocytosis and asbestosis as a source of chronic diseases.[101] 
 
From oral exposure routes, toxicity can be also observed at those higher doses. Kumari et al. 
investigated the toxicity of 28 daily oral doses of 30, 300 and 600 mg/kg bw of 24 nm 
CeO2NPs and 3 µm CeO2 microparticles in Wistar rats.
[102] Increased genotoxicity including 
DNA damage in peripheral blood leukocytes and liver were observed after exposure to 
CeO2NPs at 300 and 600 mg/kg bw/day. Significant alterations were observed in ALT and 
LDH activity in serum and reduced glutathione content (GSH) in the liver at 300 and 600 
mg/kg bw/day in a dose-dependent manner. The same authors using CeO2NPs with similar 
characteristics observed acute oral toxicity and microparticle formation in albino Wistar rats 
at 100, 500, and 1000 mg/kg bw administered through oral gavage. Results revealed that the 
highest dose of CeO2NPs (1000 mg/kg bw) induced significant DNA damage in leukocytes 
and liver cells, micronucleus formation and cytogenetic changes in bone marrow. No 
significant genotoxicity was observed at 500 and 100 mg/kg bw of CeO2NPs. Biochemical 
assays showed significant alterations in ALT and LDH activity in serum and GSH content in 






Conversely, no toxic effects are usually observed in doses of few tenths of mg or µg of CeO2 
per Kg of animal body weight. For instance, in the mentioned work of Hirst et al. where the 
administrations of CeO2NPs (3-5 nm) to CD-1 mice perorally, i.v. or i.p. (weekly for 2 or 5 
weeks; 0.5 mg/kg) was studied, no liver toxicity was observed.[72] Hijaz et al. evaluated folic 
acid conjugated 10 nm CeO2NPs as a therapeutic agent in ovarian cancer and observed that a 
twice a week i.p. treatment for 4 weeks at 0.1 mg/kg in nude mice was not associated with 
histological alterations of the liver nor alterations in the plasma biochemical measurements of 
liver function.[104] Also, i.p. administration of CeO2NPs to healthy Sprague Dawley rats (100 
nm; 0.5 mg/kg for two weeks), Albino Wistar rats (25 nm; 0.01 μg/kg; four doses distributed 
in 7 days) or BALB/c mice (<10 nm; 200 µg/kg; eight consecutive days) did not result in liver 
toxicity.[37b, 105] An implantation study, aimed to evaluate the biocompatibility of NPs 
containing biomaterials and devices, showed that local tissue reactions caused by CeO2NPs 
after 28 days of the implantation were minimal.[106] In this study, CeO2NPs did not show 
systemic toxicity or in vivo micronucleus induction in bone marrow. Chemical analysis 
showed that CeO2NPs migrated from the implant sites (250 mg per site) at low levels and 
were deposited predominantly in the liver. 
 
3.4. CeO2NPs at work in the treatment of liver diseases 
In vivo studies also present different shreds of evidence of protective effects of CeO2NPs in 
liver disease, usually related to the use of substantially lower doses than those used in toxicity 
studies (Table 2 and Figure 3). Amin et al. evaluated the ability of CeO2NPs to protect 
against monocrotaline (MCT)-induced hepatotoxicity in Sprague Dawley rats.[107] MCT is a 
pyrrolizidine alkaloid plant toxin that causes hepatotoxicity in humans and animals. I.p. 
administration of CeO2NPs (25 nm; 0.01 ug/kg) resulted in the absence of cellular alterations 
induced by MCT in rat livers examined by electron microscope imaging. Besides, it was 




transferase and significant increases in the enzymatic activities of hepatic catalase and SOD. 
This suggests that CeO2NPs are hepatoprotective agents against MCT-induced hepatotoxicity. 
Remarkably, CeO2NPs not only had a direct effect on decreasing ROS but also modified the 
transcriptome of immune cells and recruited them to synthesize more SOD and catalase to 
relieve the tissue from the deleterious inflammatory states. Such induction of immune cell 





Table 2. Studies showing therapeutic efficacy of CeO2NPs in different in vitro and in vivo models of 




Model Liver injury/disease CeO2NPs 
(size, dose, and 
administration route) 
Reference 
In vitro HepG2 cells 
(human hepatic cells) 
Oxidative stress (H2O2) 4 nm; 100 µg/ml 
[37a] 
In vitro HepG2 cells 
(human hepatic cells) 
Hyperglycemia 8.5 µg/ml [96] 
In vitro RAW264.7 cells 
(murine macrophages) 
Lipopolysaccharide 4-5 nm; 5-1000 µg/ml [97] 




1.9 nm; 5-200 µmol/L [98] 
In vitro Primary portal endothelial 
cells 
Cirrhotic rats 4 nm; 1 µg/ml [18c] 
In vitro HepG2 cells 
(human hepatic cells) 
Steatosis 4nm; 10 µg/ml [79] 
In vivo Sprague Dawley rats Hepatotoxicity (Monocrotaline) 25 nm; 0.01 µg/kg; i.p. [107] 
In vivo BALB/c-mice Hepatotoxicity (CCl4) 3-5 nm; 0.5 mg/kg; i.p. 
[15a, 72] 
In vivo Albino Wistar rats Hepatotoxicity 
(D-galactosamine and 
lipopolysaccharide) 
25 nm; 0.01 µg/kg; i.p. [105a] 
In vivo Sprague Dawley rats Peritonitis (polymicrobial) 10-30 nm; 0.5 mg/kg; i.v. [109] 
In vivo Wistar rats Liver fibrosis (CCl4) 4-20 nm; 0.1 mg/kg; i.v. 
[37a] 
In vivo Wistar rats Cirrhosis (CCl4) 4 nm; 0.1 mg/kg: i.v. 
[18c] 
In vivo Wistar rats Non alcoholic fatty liver disease (MCD 
diet) 
4 nm; 0.1 mg/kg; i.v. [110] 
In vivo Wistar rats Liver regeneration (acetaminophen) 4 nm; 0.1 mg/kg; i.v [111] 
In vivo Wistar rats Liver regeneration (hepatectomy) 4 nm; 0.1 mg/kg; i.v [112] 
In vivo Wistar rats Non alcoholic fatty liver disease 
(Neonatal monosodium glutamate) 
1-5 nm; 1 mg/kg; oral [113] 
In vivo Sprague Dawley rats Hepatic ischemia reperfusion injury 10-30 nm;0.5 mg/kg; i.v. [109] 
In vivo Sprague Dawley rats Sepsis (Lipopolysaccharide) 4-5 nm; 0.5 mg/kg; i.v [97] 
In vivo Sprague Dawley rats Hepatotoxicity 
(Doxorubicin) 
100 nm; 0.5 mg/kg; i.p. [105b] 
In vivo BALB/c-mice Hepatocellular carcinoma (DEN) <10 nm; 100-200 µg/kg; i.p. [37b] 






Figure 3. Therapeutic effects of CeO2NPs in the Liver. A-B. TEM images of CeO2NPs internalized by 
human hepatic cells (HepG2 cells) revealing the NPs morphology and localization in the cytoplasm. 
C. dark field image of a section of B allowing the NPs to be easily distinguished. D. HepG2 cells. E-F. 
Representative phase-contrast light microscopy images of HepG2 cells after H2O2 and H2O2+CeO2NPs 
treatment showing the protective effects of CeO2NPs under the oxidative stimulus. These results are 
part of our publication in Carvajal et al.[99] under the terms and conditions of the Creative Commons 




(n=8). I-L. Protective effects in different models in vivo models of rats with NAFLD and Fibrosis. 
These are preliminary results that led to works in Oro et al.[37a] and Carvajal et al.[110] For the NAFLD 
case, Wistar rats were subjected to methionine and choline deficient diet (MCDD) for 6 weeks and 
intravenously treated with CeO2NPs (0.1mg/kg) the weeks three and four of the diet. For the fibrosis 
case, CeO2NPs (0.1mg/kg) were administered to CCl4-treated rats twice a week for two weeks and 
CCl4 insult was continued for 8 additional weeks.  
 
In another study, whether CeO2NPs administration (0.5 mg/kg; 3-5 nm) would decrease ROS 
production in BALB/c-mice treated with CCl4 was evaluated.
[72] MDA in plasma was 
measured as a marker of lipoperoxidation. After 2 weeks of CCl4 administration, MDA was 
found to be lowered in CeO2NPs treated mice in comparison with non-treated animals. 
Hashem et al. evaluated the effect of CeO2NPs in hepatotoxicity induced by D-galactosamine 
and LPS in Albino Wistar rats.[105a] I.p. administration of four doses of CeO2NPs (25 nm; 
0.01 μg/kg) decreased the translocation of cytoplasmic Nrf-2 and reduced the levels of iNOS, 
TBARS (lipid peroxidation marker) and of DNA fragmentation. Also, GSH, GSH peroxidase 
(GPX1), GSH reductase, SOD and catalase hepatic levels were increased. As well, a 
significant histological improvement was observed, which suggested antioxidant and 
hepatoprotective effects in liver toxicity induced by D-galactosamine and LPS. In another 
study, the administration of a single i.v. dose of CeO2NPs (10-30 nm, 0.5 mg/kg) to Sprague 
Dawley rats with peritonitis induced by a polymicrobial insult, resulted in improvement of 
survival associated with modulation of the hepatic inflammatory response and reduced 
systemic and hepatic oxidative stress.[114] Treated rats presented less sinusoidal dilatation and 
hepatocyte congestion, reduced hepatic superoxide, lower levels of iNOS expression and 
protein nitrosylation, less monocyte and lymphocyte extravasation into the peritoneal cavity, 
decreased infiltration of macrophages into liver, a systemic decrease in the major 
inflammatory cytokines (IFN-γ, TNF-α, and IL-6) and reduction of GSH S-transferase. 
 
We evaluated systemic and hepatic protective effects of CeO2NPs in Wistar rats after a 16-
week CCl4 treatment to induce liver fibrosis.




mg/kg) twice weekly at weeks 8 and 9 reduced portal pressure without affecting mean arterial 
pressure, decreased serum ALT and AST and reduced steatosis, apoptosis, α-SMA expression 
and density of infiltrating macrophages/monocytes in the liver tissue. CeO2NPs also reduced 
hepatic expression of inflammatory mediators such as IL-1β, TNF-α, iNOS and COX-2 and 
the vasoconstrictor endothelin-1. Interestingly, CeO2NPs significantly reduced hepatic 
macrophages M1 abundance (pro-inflammatory function; genes TNF-α and iNOS) but did not 
modify M2 marker expression (macrophages with immunoregulatory function; 
genes CD163, Arg1 and MRC2). CeO2NPs also reduced hepatic mRNA overexpression of 
genes related to oxidative stress (Epx), superoxide metabolism (Ncf1 and Ncf2) and ER stress 
(Atf3 and Hspa5) and rescued messenger expression of PPARγ.[37a] In another study, we 
evaluated the effect of albumin coated 4 nm CeO2NPs in primary endothelial cells isolated 
from the portal vein of cirrhotic rats and found that CeO2NPs treatment reduced the 
proinflammatory state of endothelial cells promoting M2-like phenotype (anti-
oxidant/regenerative) and reducing M1 polarization (pro-oxidant/defensive) in macrophages 
that were exposed to endothelial cell-conditioned medium.[18c] The beneficial effect of 
CeO2NPs was also linked with differential expression of vasoactive and extracellular matrix 
remodeling genes that resembled the gene signature found in endothelial cells isolated from 
healthy animals. Furthermore, cirrhotic rats treated with these CeO2NPs normalized MDA 
levels in the portal vein and showed and histological improvement of the portal vein 
endothelium monolayer assessed by scanning electron microscope. 
 
In addition to these, we have also found significant beneficial therapeutic effects of CeO2NPs 
in experimental models of non-alcoholic fatty liver disease (NAFLD), hepatocellular 
carcinoma and liver regeneration. CeO2NPs treatment (4 nm, albumin coated, 0.1 mg/kg) of 
Wistar rats fed with a methionine and choline deficient diet for 6 weeks resulted in reduced 




In addition, the same type of CeO2NPs administered to Wistar rats with liver hepatocellular 
carcinoma (induced by a weekly i.p. injection of DEN for 16 weeks) improved overall 
survival, similar to the multikinase inhibitor sorafenib, which was associated with lower 
hepatic cell proliferation rate, less macrophage infiltration, specific changes in protein 
phosphorylation and several lipid components, and reduced levels of the tumor marker α-
fetoprotein.[37c] We also assessed the effect of the CeO2NPs treatment on hepatic regeneration 
in Wistar rats after liver injury by acetaminophen overdose or after 2/3 partial hepatectomy 
(PHx).[111-112] In both conditions, CeO2NPs treatment stimulated hepatocyte proliferation and 
decreased early liver damage, indication a beneficial effect of the CeO2NPs in liver tissue 
regeneration. 
 
To add some more examples, Kobyliak et al. reported anti-inflammatory properties of 
CeO2NPs on a NAFLD rat model associated with neonatal monosodium glutamate induced 
obesity.[113b] Oral administration of CeO2NPs (1-5nm; citrate stabilized; 1 mg/kg) for 3 
months in 2 two-week courses resulted in a 35% decrease in body weight and a 20% decrease 
in liver lipids and triglycerides. In another study using this model, the same authors found that 
orally administered CeO2NPs improved liver histology and decreased lipid peroxidation.
[113a] 
Manne et al. evaluated the protective effects of CeO2NPs administration on hepatic ischemia 
reperfusion injury in Sprague Dawley rats.[109] Partial warm hepatic ischemia was induced 
during 1 hour followed by 6-hour reperfusion. Prophylactic treatment with CeO2NPs (10-30 
nm, 0.5mg/kg), i.v. administered 1 hour before the hepatic ischemia and reperfusion, 
decreased serum levels of hepatocellular injury markers (ALT and LDH) and hepatocyte 
necrosis, preserved normal histological hepatocellular architecture and reduced several serum 
inflammatory markers (macrophage-derived chemokine, macrophage inflammatory protein-2, 
KC/GRO, myoglobin and plasminogen activator inhibitor-1). These results suggest that 




failure. I.v. injection of agglomerates of 4-5 nm CeO2NPs (0.5 mg/kg; polyphenol stabilized) 
in Sprague Dawley rats with LPS-induced sepsis, reduced mortality, liver apoptosis, and 
hepatic iNOs and HMBG-1, showing potential use of CeO2NPs as a healing agent for liver 
sepsis.[97]. I.p. administration of CeO2NPs (100 nm; 0.5 mg/kg once a week) to Sprague 
Dawley in rats simultaneously treated with doxorubicin for two weeks reduced the hepatic 
toxicity of this chemotherapeutic agent as assessed by histological and structural studies and 
decreased AST, ALT and MDA levels.[105b] The hepatoprotective potential of CeO2NPs (<10 
nm) was also assessed in BALB/c mice with diethylnitrosamine (DEN) induced 
hepatocellular carcinoma that were pretreated i.p. with CeO2NPs (100 μg/kg or 200 μg/kg) 
daily for eight consecutive days.[37b] DEN (200 mg/kg) was administered 48 h before the 
animals were sacrificed. Results show that CeO2NPs attenuated the activities of antioxidant 
enzymes and expression of Bcl-2 and COX-2 suggesting protection from DEN-
induced liver damage via antioxidative activity.  
 
4. CeO2NPs in medical applications. Advantages and proposed mechanisms of action 
 
Despite the described beneficial effects of CeO2NPs in many medical conditions, the in vivo 
mechanisms are not yet totally elucidated and they are difficult to clarify via biological 
experiments.[20b] Following the discovery of the therapeutic potential of CeO2NPs, it was 
rapidly thought that they could provide to the field of medicine an effective long-lasting 
antioxidant compound for the treatment of a broad spectrum of diseases associated with free 
radical production, especially in diseases related to chronic inflammation and aging.[44, 60] This 
has been explained by the capacity of CeO2NPs to participate in biological processes 
mimicking the activity of enzymes such as catalase,[115] SOD[38a, 116] and peroxidase.[117] 
Afterward, other NPs, mainly TiO2 and Fe3O4, have been found to be useful in similar 




was proposed and their intended applications were expanded towards the modification of 
pathological microenvironments.[18] In this section, their advantages and proposed 
mechanisms of action are reviewed, focusing on the case of CeO2. 
 
In section 2 it has been introduced the huge rise of popularity of antioxidants since the 1990s 
and how classic antioxidant substances-such as SOD, ascorbic acid, resveratrol, colchicine, 
eugenol or vitamin E- have shown limited success in clinical applications, in what has been 
called the antioxidant paradox.[118] Even more, they have raised controversies after several 
unsuccessful clinical trials.[61-62] Several shortcomings of those antioxidant agents may 
account for these failures. One of them is the to-date inability to design efficient antioxidants 
with targeted and controlled activity. In many clinical trials, the type and dosage of 
antioxidants did not address the oxidative stress in a tissue- or cell-specific manner (i.e., on 
target) and therefore did not produce any effect or even contrary effects.[119] Another factor is 
the limited reaction capabilities of antioxidant molecules, which often scavenge only one 
single free radical before being inactivated. This is also related to the reaction environment. 
For instance, while vitamin C acts in the intracellular and extracellular environments, vitamin 
E acts in the membrane. CeO2, in its NP form, can overcome these drawbacks (Table 3). 
First, because NPs can be easily functionalized with targeting peptides or molecules and thus 
designed to have a controlled biodistribution. Although these developments in the case of 
CeO2NPs are still incipient, some studies already show this possibility, e.g. the works of Li et 
al.[120] and Xu et al.[121] Second, because CeO2NPs have a long-lasting antioxidant activity due 
to the high number of reactive sites. This is a major difference between classic antioxidants 
and CeO2NPs. Whereas the former are quickly oxidized (metabolized), CeO2NPs, may work 
without being entirely consumed during the reaction. Thus, even at low doses, they can be 
more effective and with sustained activity over time. Finally, limited by the low O2 




thus acting as a redox buffer,[10] i.e. CeO2NPs are only “active” in the presence of 
pathological ROS levels. 
 
Table 3. Summary of the advantages of CeO2NPs respect classic antioxidants. 
Classic antioxidants CeO2NPs 
No targeted activity. It can be functionalized, controlled biodistribution. 
Limited activity: often scavenge one free radical. Multienzymatic: catalase-like, SOD-like, peroxidase-like 
activities, NO scavenging, etc. and can participate in the 
multiplicity of cross-reactions between ROS and 
inflammation. 
Limited activity: they are metabolized; after reaction 
become inactivated. 
Not entirely consumed during reaction and thus can work 
at low doses. 
Limited activity: short half-life. Long residence time in tissue. 
No controlled activity (they become inactivated after 
reaction). 
ROS buffers: only act in conditions of ROS overproduction. 
Safe Safe (degraded in innocuous Ce3+ ions and expulsed from 
the body). 
 
A third reason that accounts for the antioxidant paradox is the limited understanding of the 
ephemeral nature of ROS/NOS, and also of the interdependence between oxidative stress and 
inflammation. [119, 122] To add more complexity, the network of antioxidants is complex itself 
and interrelated (for instance, SOD can catalyze but it, in turn, produces another ROS, H2O2, 
as a product).[123] Briefly, ROS and NOS are a variety of molecules including superoxide, 
H2O2, hydroxyl free radical, nitric oxide, peroxynitrite, and hypochlorous acid. They are 
produced naturally as a result of cell metabolism and have an important role in a wide variety 
of cellular responses, including cell growth, immunity, control of hormone concentration and 
enzymes activity.[124] The physiological functions of ROS are possible thanks to redox 
homeostasis, i.e, the presence of a balance between ROS formation and its elimination by 
endogenous antioxidant systems, mainly composed of glutathione peroxidases, SODs, 
catalases, thioredoxins, and vitamins C and E.[125] When the redox equilibrium is altered (by 
an increase in ROS production and/or insufficient response of the natural defense systems), 




mutagenesis), protein degradation and lipid peroxidation. These reactions ultimately lead to 
inflammatory processes.[126] Inflammation itself triggers a higher ROS production as a 
defense mechanism to generate a less biofriendly environment against pathogens, especially 
by the innate immune system.[127] This, in the case of some channelopathies, results in 
epilepsy crisis.[128] 
 
Therefore, the excess of ROS induces inflammation. But the reverse sequence of events is 
also true: inflammation induces ROS to alter immune cells phenotype and activate them in a 
sort of positive reciprocal feedback loop.[119, 122] During the inflammatory response, phagocytic 
cells become activated and produce large amounts of ROS and reactive nitrogen and chlorine 
species to eliminate commensal organisms.[129] And these reactive species diffuse out of the 
phagocytic cells, inducing in turn oxidative stress and tissue injury what triggers an immune 
response and more ROS into a vicious loop. Several mechanisms of ROS-induced activation 
of inflammatory mediators and DNA modifications have been reported.[130] Thus, selection of 
antioxidants that do not inhibit both processes -ROS production and inflammatory response- 
or the use of molecules that block some of the oxidative and/or inflammatory pathways but 
may trigger the others, could account for unsuccessful antioxidants performance in clinical 
trials.  
 
In this context, CeO2NPs also display superior activity respect the limited reaction capabilities 
of classical antioxidants. They can act mimicking the activity of many of the different 
endogenous antioxidant molecules and they can participate in the multiplicity of the cross-
reactions between ROS and inflammation at any level which allows disconnecting these two 
events (Figure 4). During the last two decades, it has been described for CeO2NPs the SOD 
activity (conversion of superoxide anion into hydrogen peroxide and finally oxygen),[116, 131] 




(hydrogen peroxide into hydroxyl radicals),[117] as well as of NO scavenging ability,[132] 
among others. Remarkably, these proposed small size NPs become a rather inert material at 
healthy physiological conditions, slowly dissolving into innocuous cerium ions that are finally 
expulsed via the urinary tract or the hepatic route.[18c, 37a, 89d]  
 
 
Figure 4. Sources of inflammatory and oxidative stress processes and their interrelation. Here, 
CeO2NPs can act at different levels, breaking the vicious cycle between inflammation and oxidative 
stress. 
 
This wide free radical scavenging activity is often pictured by an ability of CeO2NPs to 
participate in those reactions through an auto regenerative redox cycles switching the valence 
states between Ce3+ and Ce4+. While most of the research works on the therapeutic activity of 
CeO2NPs refer to this mechanism, others have been also proposed in biological contexts. 
Cafun et al. using synchrotron light, observed that the Ce(4f) orbitals remain unchanged even 
when particle size decreases below 4 nm.[115a] And they remained so, even during the 
decomposition of H2O2 (catalase mimetic activity) in model cell culture media. In those high 
energy resolution experiments, a different mechanism was proposed. Since there is no sign of 
a redox partner (a local Ce3+ site), alterations of the electron density in 5s orbitals suggest that 
the reaction may take place due to a charge enrichment delocalized over the atoms of the NP, 
acting as a sort of electron sponge. Thus the NP would be not exactly CeO2 but, CeO1,99 
(assuming 150 atoms of Ce per NP and one oxygen vacancy), delocalized in such a way that 




are analyzed with a scanning tunneling probes.[133] In any case, although the mechanism is still 
to be completely understood, the use of CeO2NPs already constitutes a disrupting and 
promising new therapeutic alternative in the many conditions related to chronic inflammation, 
with activity superior to classic antioxidants. 
 
5. Toxicity and Safety. A remaining challenge  
 
Despite the interesting advantages of nanomaterials for medicine and the promising research 
results obtained, only a few of them have reached the bedside. In the case of inorganic NPs, 
those are mainly based in iron oxide NPs, e.g. as iron replacement therapy for the treatment of 
anemia.[29a] Other nanomaterials are already approved e.g. by the American Food and Drug 
Administration for clinical trials, which mainly include liposomes or organic particles and 
also some metal and metal oxides NPs such as Au, SiO2 and iron oxide NPs.
[29a, 134] 
Economical and technical aspects slow down the path towards making nanomedicine 
potentialities a reality. Of course, for any drug development enterprise, investments for new 
drugs and medical technologies to reach the market and the patients are enormous, derived by 
the economic conservative exploitation model and the consequent financial needs. Regarding 
knowledge and technical aspects, a major shortcoming is that the safety of nanomaterials is 
still a subject of wide debate. In the scientific literature, there are confusing and contradictory 
results. For instance, for the mentioned case of iron oxide NPs, inhalation exposure of 
different iron oxide and iron spinel oxide NPs with sizes ranging from 10 to 60 nm have been 
found to increase levels of DNA strand breaks in an study with female C57BL/6J BomTac 
mice, showing the potential pulmonary toxicity of these type of nanomaterials.[135]  
 
The case of CeO2NPs is again a paradigmatic example. For this material, along with the 




other studies indicate the opposite, a role of this nanomaterial on promoting oxidative stress, 
decrease in cell viability through autophagy and apoptosis and inflammation (see e.g. 
Fisichella et al.)[136] Specifically in liver, as reviewed in section 3, some reports show CeO2 
NPs uptake by hepatocytes with beneficial anti-inflammatory effects while others show 
macrophage (Kupffer cells) uptake with pro-inflammatory effects. In this section, the sources 
of these discrepancies are discussed and several considerations are proposed.  
 
5.1. Different morphological characteristics. 
 
At the source of these discrepancies, there are different factors. One of them is the diversity of 
materials actually employed. This relates to the multiplicity of works that include a wide 
variety of different particles in terms of sizes, surfaces states, concentrations, stabilities and so 
on. In such cases, the results from one study can not be generalized and/or translated to other 
studies without a careful look at the characterization details of the material. In the case of 
CeO2NPs, different formulations are presented under the same CeO2 nanoparticles or 
nanoceria or nanocrystalline cerium dioxide or similar labels (Figure 5). Indeed, the effects 
of CeO2NPs as “active ingredient” depend on the formulation of the final product in which 
they are presented. Different reagents and procedures are employed to prepare CeO2NPs 
yielding NPs with different surface states and/or embedded in colloidal solutions with 
different stabilizers. For instance, Dowding et al. prepared different samples of CeO2NPs 
using identical precursor (Cerium Nitrate Hexahydrate) through similar wet chemical process 
but using different reagents for their synthesis and stabilization: H2O2, NH4OH, or 
hexamethylenetetramine (HMT).[137] Results showed that, unlike the other CeO2NPs 
preparations, HMT- CeO2NPs were readily taken into endothelial cells and reduced cell 
viability at a 10-fold lower concentration than the others, attributed to HMT. Another example 






Figure 5. TEM images of different samples of CeO2NPs with different sizes, shapes and size 
distributions, all labeled as CeO2NPs. Scale bars are 20 nm; A) 4 nm CeO2NPs, synthesized with 
Ce(NO3)3 and TMAOH; B) 15 nm CeO2NPs synthesized with Ce(NO3)3 and HMT; C) CeO2 
nanorods; D) Commercial CeO2NPs in dry form after resuspension in H2O; E) Commercial CeO2NPs 
in dry form after resuspension in Cell Culture Media (CCM). 
 
Different works have attempted to describe trends between NPs morphology, surface 
characteristics and biological outcome. Asati et al., exposing polymer-coated CeO2NPs with 
positive, neutral and negative surface charges to normal and cancer cell lines showed the 
differences in internalization and toxicity.[138] Positive and neutral charged NPs were uptaken 
by all cell lines studied, while negatively charged NPs were uptaken only in the cases of 
cancer cell lines. Differences in subcellular localization depending on the NPs surface charge 
were also shown, being significantly toxic only when they localize in the lysosomes of the 
cancer cells. Fisichella et al. also showed how surface modifications affected cytotoxicity 
results.[136a] In this study, non-coated CeO2NPs down-regulated key genes involved in 
metabolic activity while ammonium citrate capped CeO2NPs did not display any adverse 
effect at the same concentration. Regarding morphologies, Ji et al. observed that CeO2 
nanorods (with different lengths from hundreds of nanometers to micrometers) induced a 
progressive increase in IL-1β production by generating lysosomal damage while CeO2 
nanospheres and shorter nanorods did not show significant toxicity.[139] Here, it is important to 




phagocytosis, leading to chronic inflammation. However, this is the case of microstructures 
(single crystal or aggregates) rather than isolated nanostructures.[140]  
 
Consequently, the variability of the nanomaterials used and their, sometimes, poorly 
described characterization are barriers to the development of this multidisciplinary area. This 
is of high importance in the case of nanometric size NPs, where minor variation in the NPs 
morphology may have a large impact on the biological outcome. Indeed, to test all the 
possible variations to have a complete picture of NPs safety aspects is a cumbersome task but 
different strategies to decrease the burden of work for nanomaterials safety assessment have 
been proposed and reviewed elsewhere.[27, 141] 
 
5.2. Different evolution in biological environments. Extrinsic properties of 
nanomaterials 
 
Another source of the discrepancies between beneficial and detrimental NPs effects is the 
different evolution of the actual materials being tested. Cellular environments and 
physiological media contain different and higher ionic and molecular compositions than the 
NPs synthesis media. Similarly, there are different redox states (from rather reducing to 
oxidizing) and different pHs (the late endosome and lysosomes can go down to 5) inside 
tissues and cellular structures, as well as the presence of nucleophilic species and ionic 
scavengers. The processes that NPs undergo in these conditions are diverse and a variety of 
parameters are involved. These have been also described and reviewed elsewhere.[1b, 73a, 142] 
Generally, it has been described the agglomeration into submicrometric or even micrometric 
particles,[142b] the corrosion and dissolution into molecular or ionic species,[89a-c, 143] and the 




forming the so-called Protein Corona.[144] In addition, all these processes may take place 
simultaneously and with different temporal evolutions, which difficult their study (Figure 6).  




stable NPs dispersed in physiological environment. Protein Corona and Dissolution take place 
simultaneously and with different time evolutions. Eventually, NPs are dissolved and expulsed by 
urine as reported for the case of CeO2NPs; B. TEM image of 10 nm CeO2NPs synthesized in the 
laboratory as described in Cafun et al.[115a] Scale bar is 100nm; C. UV-VIS spectra of NPs from image 
B as-synthesized and after 48 hours dispersed in Cell Culture Media (CCM) consisting of DMEM + 
10%FBS); D. Schematic representation of the time evolution of unstable NPs dispersed in 
physiological environment. Aggregation takes place at short times, which slows down dissolution, 
while Protein Corona stabilizes the agglomerates formed initially; E. TEM image of commercial CeO2 
nanopowders dispersed in CCM and with a nominal size of 25 nm according to the manufacturer. 
Scale bar is 100nm; F. 48 hours evolution of the UV-VIS spectra of NPs from image E dispersed in 
CCM. 
 
Importantly, all these modifications depend to a large extent on the characteristics of the 
biological media in which NPs are dispersed. Therefore, their biological effects will depend 
not only on the NPs intrinsic properties (characteristics such as size and shape) but also 
extrinsic (characteristics of the exposure media, such as the ionic strength, pH, molecular 
content, etc). These extrinsic features modify the morphology, surface state and hence, affect 
the activity, biodistribution, and fate of the NPs, as we reviewed recently.[145] This is 
especially critical in the case of NPs since their activity depends largely on their surface 
chemistry and characteristics. Thus, the safe and effective use of promising therapeutic NPs 
needs not only a proper evaluation of possible unwanted (toxic) effects but also the 
understanding of their precise evolution and biodistribution (ADME profiles) inside the 
human body.[142c, 146] In this scenario, the development of reproducible and reliable analytical 
methods for the dynamic characterization of the evolution of nanomaterials in biological 
environments is recognized as a pressing need to perform reliable nanosafety studies. This 
was pointed out e.g. back in 2012 in an editorial of Nature Nanotechnology,[147] and more 
recently, for the specific case of a type of NPs (nanozymes) by the news and opinion of 
Ghorbani et al.[24] 
 
The challenges that this characterization involves are exemplified in the recent work of 
Carlander et al.[148] These authors attempted to test the appropriateness of a physiologically 




experimental biokinetic data from the literature and results from research works with 
CeO2NPs with different sizes, coatings, and doses, administered to rats through various 
exposure routes. The authors could fit the results into the model in only one specific case, 5 
nm CeO2NPs citrate capped. Conversely, the model failed for other types of NPs since, as the 
authors acknowledge, “overall, the modeling results suggest that the biokinetics of CeO2NPs 
depend not only on the properties of NPs (size and coating) but also, and even more so, on the 
exposure conditions (route and dose)”.[148]  
 
In this context, it is worth noting that the majority of negative immune effects reported in the 
scientific literature are related to NPs aggregation and contamination, which cause biological 




[151] NPs showed similar toxicity to CeO2NPs 
aggregates.[100, 152] In the case of Fe3O4NPs, one of the first inorganic nanomaterial employed 
in biomedical research,[153] in the same year one report showed promising nerve cell 
regeneration activity[154] while others found toxicity to neuronal cells.[155] Another example is 
the mentioned work of Hadrup et al.[135] where the conversion of mass-dose into specific 
surface-area-dose showed that inflammation correlated with the deposited surface area, 
highlighting once more that the evolution in the physiological environment is of paramount 
importance. Furthermore, CeO2NPs have been reported to be pro-oxidant (instead of anti-
oxidant) depending on its aggregation state,[137, 152, 156] and chronic exposure to CeO2NPs 
aggregates was found to be associated with increased levels of ROS and heat shock stress 
response.[152] In turn, generally, isolated, non-contaminated NPs consistently show no toxicity 
and, in the case of NPs, displaying therapeutic benefits, e.g. references in section 3.4 and 





Even more, due to their industrial applications, most of the research on the toxicity of 
CeO2NPs has been done to assess occupational and environmental exposure. In such studies 
often industrial CeO2 nanomaterials were employed, which were normally polydisperse, poly-
aggregated and contaminated. As well, this type of material is often supplied in dry 
aggregated form, that further aggregate in biological fluids (Figure 6E-F).[142b, 157] In those 
studies, toxic effects were often found. Nowadays, these toxic effects have been attributed to 
aggregation and contamination of samples.[146] Besides, in these types of studies, the 
administered doses are usually higher than those proposed in nanomedicine.  
 
5.3. Towards the next generation of NPs for medical applications 
The present discussion for the case of CeO2NPs can be extended to other NPs intended for 
medical applications. For any NP, bioactivity operates on a scale where NP morphology, 
environment and behavior are strongly coupled. Thus, sometimes results observed have been 
wrongly attributed to the object tested without a characterization of its evolution in operando. 
Other times, poorly described nanomaterials have been used, which difficult to infer any 
structure-activity correlation. Nowadays, a large amount of data regarding NPs activity has been 
gathered but little progress made towards matching expectations since some key parameters 
such as their stability in the physiological media (agglomeration or degradation) and protein 
corona formation, the impact of pH and temperature and biodistribution, clearance and 
excretion routes have not been properly addressed in most of the papers.[24, 146] 
 
In this scenario, providing highly soluble NPs in the physiological media is a requirement for 
their meaningful and controlled use. As said, this is especially significant in the case of NPs. 
From one side, and as for any other nanomaterial, because their stability will determine the 




agglomeration, protein corona formation, and dissolution modify surface properties and 
available surface areas. Advances in NPs preparation are significantly boosting the progress in 
nanomedicine research and can overcome some of these challenges. For instance, the design 
of nanostructures with a core-shell architecture is known to improve the physical and 
chemical properties of the composite by providing a protective interface to the NPs and 
combining other functionalities on a nanoscopic length scale.[158] Polymeric NPs and 
liposomes have traditionally been among the most commonly used materials for such 
purposes (see e.g. Sailor et al).[159] More recently, metal-organic frameworks, dendrimers, and 
silica-based inorganic hybrid NPs have been explored.[160] However, this surface engineering 
may lead to the reduction of the surface area available for NP reactivity. One simple and 
effective solution could be to promote NPs solubility by pre-albuminizing them during the 
preparation process.[18c, 79] Since the formation of agglomerates in physiological media may 
occur rapidly, the design of NPs stabilized with albumin prior aggregation during their 
synthesis allowed to obtain NPs more stable and with higher activity, which recalls the 
successful case Abraxane®, one of the first approved nanomedicines.[161]  
 
In summary, some critical determinants that need to be carefully addressed to drive the NPs 
clinical benefits towards their clinical translation are depicted in Figure 7 and can be grouped 
into the following: i) the development of ADME and nanopharmacokinetics models for NPs 
to the understand their precise biodistribution and evolution inside the human body; ii) the 
application of standardized operating procedures for their dynamic characterization in the 
physiological media; iii) the consideration of underappreciated parameters, such as the 
morphological characteristics of different materials labeled uniformly as “nanoparticles” and 
possible contamination of the samples; iv) the development of well-dispersed NPs in solution 






Figure 7. Considerations discussed in this work towards the next generation of NPs for medical 
applications. 
 
Conclusion and outlook. 
In this review, we have highlighted some general trends after these almost two decades of 
work with CeO2NPs for medicine, which can be applied to other NPs. First, as other NPs, 
after i.v. administration they passively accumulate in liver and spleen (up to 90-95% of the 
administered dose) with a minor fraction identified in the lung and kidneys, and minimal or 
undetectable in other organs. Thus, it can be easily understood that the liver represents a 
major testing field for the study of the evolution and therapeutic effects of NPs and their 
clinical translation. Remarkably, the knowledge gained in the liver would be also of 
importance for future applications in other organs when properly targeted therapies will be 
developed. 
 
Following their liver accumulation, it could be concluded that CeO2NPs generally do not 
show toxicity in vitro neither in healthy rodents under standard therapeutic doses and remain 
in the liver for a long time after their administration (at least months). After this time, 
CeO2NPs degrades into innocuous Ce
3+ ions that are expulsed via the kidney. This situation 
has been also shown for the other proposed NPs.[162] It can also be observed that CeO2NPs 




animal), while they display hepatoprotection against different induced damages at doses up to 
1 mg/kg bw. A similar trend is observed in vitro, where NPs used at higher doses, and/or 
when they precipitate in the cell culture media, compromise cellular viability. Conversely, 
CeO2NPs usually show cellular protective effects against different insults, at doses from 1 to 
100 µg/ml. Thus, NPs biokinetics will depend largely on NPs characteristics, evolution in the 
physiological media, the dose employed and the exposure route. For all this, we aimed to 
provide in section 3 the most of the published studies available regarding the characteristics 
and doses of the NPs used mainly for liver disease treatment, since this information is critical 
to understand the biological results obtained by independent groups of researchers.  
 
Still, some work needs to be done before the appealing properties of NPs can arrive to patients 
and society. This has been discussed in sections 4 and 5. First, mechanisms of action are still 
to be completely elucidated and understood. Most of the works in scientific literature where 
the antioxidant activity of NPs is intended for medical applications are mainly focused on the 
therapeutic outcome and much less to the clarification of the mechanisms. Theoretical and 
experimental work on the performance of NPs in the physiological environment must be 
coupled with the nanomaterial evolution in the working media and the precise knowledge of 
their cellular and subcellular distribution. For instance, in the specific case of liver, the 
different relative hepatic uptake of NPs by hepatocytes and Kupffer cells (which depends on 
NPs size and solubility, i.e., their colloidal stability) makes it difficult to certainly determine 
where and how the NPs may function. In addition, a comprehensive evaluation of the safety 
aspects is needed. Along with toxicity aspects, it must include the NPs in vivo stability and 
their pharmacokinetics, biodistribution, and fate. Here, one of the advantages of working with 
inorganic NPs is that they have physical (and chemical) signatures very different from 




Indeed, biodistribution and fate must be considered in healthy and disease models. A good 
compilation of available characterization techniques for these purposes has been recently 
reviewed by Modena et al.[3] Another question that will need further work is whether those 
described beneficial effects would be good enough and powerful enough to redress biological 
states also in the long term, or on the contrary, they could pose potential toxic effects. 
 
The next unavoidable step towards the clinical use of CeO2NPs is to have them produced under 
GMP conditions. Their preparation and development under these conditions are not especially 
challenging since it can be a simple one-step reaction. The most critical part would be the 
procurement of GMP reagents for the synthesis since these types of materials are not on the 
drug discovery pipeline of chemicals producers. The development of a pharmacological product 
(with the characteristics of isotonic, endotoxin-free, sterile and stable) will also require the strict 
definition of the NPs characteristics. This refers to their size, monodispersity, NPs purity and 
colloidal stability, and the presence of excipients and potential by-products. In addition, it 
would be needed studies of stability (shelf-life) of the product and the tolerance to 
specifications, aspects that the scientific community seems, at this stage, to be able to address 
successfully. Here, we would like to note that a combination of simple spectroscopy analysis 
of the NPs such as UV-VIS, Dynamic Light Scattering, and Z-potential measurements may 
provide precise signatures of the samples since these techniques are extremely sensitive to NPs 
alterations. Finally, approval by the regulatory agencies has to be obtained. For this, CeO2NPs 
will have to follow a similar process as the mentioned case of Fe3O4NPs, already approved by 
the EMA and FDA for different medical uses, as contrast agent for MRI (Resovist®), as iron 
supply in the case of ferropenic anemia (Feromuxytol®), or as hyperthermia agent to treat 





For this translation, and following e.g. FDA guidance for industry on drug products, including 
biological products, that contain nanomaterials,[163] it is acknowledged that nanotechnology 
can be used in a broad array of FDA-regulated products, being the active ingredients, carriers 
or adjuvants and that their inclusion may modify significantly the substance behavior. It is 
important to note that the FDA does not categorically judge all products containing 
nanomaterials as intrinsically benign or harmful. It is recognized that the nanoform of a 
substance may change dissolution rates and that NPs can be passively or actively targeted to 
different sites within the body. Hence, particular physicochemical analysis is needed to define 
and control the product and ADME considerations have to be revisited for NPs. Finally, the 
clinical development of drug products containing nanomaterials should follow all policies and 
guidelines relevant to clinical safety and efficacy studies as any other substance, taking into 
account their particular physicochemical properties. All this should be an integral part of the 
future work where chemists, material scientists, molecular biologists, and medical doctors 
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Figure 1. Different reactions and applications in which CeO2NPs are being proposed or used as 
antioxidant NPs. A) In nanomedicine research. References are, to the best of our knowledge, the first 
study reporting the application. We apologize in advance if other contributions were before the ones 
here listed. Abbreviations: SOD: M=Cu (n=1); Mn (n=2); Fe(n=2); and Ni (n=2); Catalase: Fe(III)-E 
(heme group iron center attached to catalase; Fe(IV)-E•+  (mesomeric form of Fe(V)-E, i.e.,iron not 
completely oxidized to +V); Peroxidase: The electron donor is very dependent on the structure of the 
peroxidase. They also may contain in their active site, among others, a heme cofactor or redox-active 
cysteine or selenocysteine residues. B) In three ways catalytic converters, where I. Oxidation of unburnt 
hydrocarbons; II. Oxidation of Carbon Monoxide (CO); III. Reduction of Nitrogen Oxides to Nitrogen; 












Figure 3.  
 
 
Figure 3. Therapeutic effects of CeO2NPs in the Liver. A-B. TEM images of CeO2NPs internalized by 
human hepatocytes (HepG2 cells) revealing the NPs morphology and localization in the cytoplasm. C. 
dark field image of a section of B allowing the NPs to be easily distinguished. D. HepG2 cells. E-F. 




treatment showing the protective effects of CeO2NPs under the oxidative stimulus. These results are 
part of our publication in Carvajal et al.[99] under the terms and conditions of the Creative Commons 
Attribution (CC BY) license. H. Organ distribution upon administration of CeO2NPs after 8 weeks 
(n=8). I-L. Protective effects in different models in vivo models of rats with NAFLD and Fibrosis. 
These are preliminary results that led to works in Oro et al.[37a] and Carvajal et al.[110] For the NAFLD 
case, Wistar rats were subjected to methionine and choline deficient diet (MCDD) for 6 weeks and 
intravenously treated with CeO2NPs (0.1mg/kg) the weeks three and four of the diet. For the fibrosis 
case, CeO2NPs (0.1mg/kg) was administered to CCl4-treated rats twice a week for two weeks and CCl4 










Figure 4. Sources of inflammatory and oxidative stress processes and their interrelation. Here, 












Figure 5. TEM images of different samples of CeO2NPs with different sizes, shapes and size 
distributions, all labeled as CeO2NPs. Scale bars are 20 nm; A) 4 nm CeO2NPs, synthesized with 
Ce(NO3)3 and TMAOH; B) 15 nm CeO2NPs synthesized with Ce(NO3)3 and HMT; C) CeO2 
nanorods; D) Commercial CeO2NPs in dry form after resuspension in H2O; E) Commercial CeO2NPs 







Figure 6.  
 
 
Figure 6. CeO2NPs from different sources. A. Schematic representation of the time evolution of 
stable NPs dispersed in physiological environment. Protein Corona and Dissolution take place 




urine as reported for the case of CeO2NPs; B. TEM image of 10 nm CeO2NPs synthesized in the 
laboratory as described in Cafun et al.129 Scale bar is 100nm; C. UV-VIS spectra of NPs from image B 
as-synthesized and after 48 hours dispersed in Cell Culture Media (CCM) consisting on DMEM + 
10%FBS); D. Schematic representation of the time evolution of unstable NPs dispersed in 
physiological environment. Aggregation takes place at short times, which slows down dissolution, 
while Protein Corona stabilizes the agglomerates formed initially; E. TEM image of commercial CeO2 
nanopowders dispersed in CCM and with a nominal size of 25 nm according to the manufacturer. 
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Table 1. Firsts and recent reports using CeO2NPs in different medical areas. 
 
Yeara) Area Description of the work 
2003 First use in 
nanomedicine 
CeO2NPs of less than 20 nm prolonged the lifespan of brain cell cultures, for periods 
of up to 6-8 months.[30] 
2005 Oncology Protection from radiation-induced damage: CRL8798 cells (immortalized normal 
human breast epithelial cell line) and MCF-7 (breast carcinoma cell line) were 
exposed to radiation. Further treatment with CeO2NPs was shown to confer 
radioprotection to the normal human breast line but not to the tumoral one.[38a]. 
Other, more recent, works can be found e.g. in Li et al.[38b] and Nourmohammadi et 
al.[38c]  
2006 Neurology CeO2NPs were found to be neuroprotective, limiting the amount of ROS that would 
decrease viability of nerve cells (HT22 hippocampal nerve cell line).[32a] 
Neuroprotective effect on adult rat spinal cord neurons demonstrated with 
electrophysiological recordings of retention of neuronal function in cultured cells 
isolated from rat spinal cords.[71] Other, more recent, works can be found e.g. in 
Kalashnikova et al.[32c] and Ranjbar et al.[32d] 
2006 Ophthalmology CeO2NPs prevented retinal degeneration induced by intracellular peroxides -and 
thus preserve retinal morphology and prevent loss of retinal function- in an in vitro 
primary cell culture of dissociated cells of the rat retina and an in vivo albino rat 
light-damage model injecting the suspension of CeO2NPs into the vitreous of both 
eyes.[31a] Other, more recent studies, can be found e.g. in the works of Cai et al.[31b, 
31c] 
2007 Cardiology Intravenously injected CeO2NPs in a transgenic murine model of cardiomyopathy 
reduced the myocardial oxidative stress, the endoplasmic reticulum stress and 




In vivo study show CeO2NPs potential to reduce ROS production in mice states of 
inflammation and hence proposed as a novel therapy for chronic inflammation.[15a] 
2011 Diabetes A combination of CeO2NPs and sodium selenium was beneficial to diabetic rats.
[35a] 
Another, more recent, work can be found e.g. in Khurana et al.[35b] 
2013 Hepatology CeO2NPs showed similar performance as N-acetyl cystine, a common therapeutic 
to reduce oxidative stress, in mice with induced liver toxicity (by CCl4).
[72] Other, 
more recent works can be found e.g. in Adebayo et al.[37b] and Fernandez-Varo et 
al.[37c] 
2014 Regenerative 
Medicine and tissue 
engineering 
The capacities of CeO2NPs to achieve functional restoration of tissue or cells 
damaged through disease, aging, or trauma through enhancing long-term cell 
survival, enabling cell migration and proliferation, and promoting stem cell 
differentiation were reviewed in the work of Das et al.[39] Another more recent work 
can be found e.g. in Marino et al.[40]  
2017-
2019 
NPs in the space CeO2NPs to counteract the detrimental effects of microgravity-induced oxidative 
stress.[41] 
a)To the best of our knowledge, we briefly describe here the firsts reports, and more recent ones, that 
apply the therapeutic potential of CeO2NPs in nanomedicine research. We apologize in advance if 
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Table 2. Studies showing the therapeutic efficacy of CeO2NPs in different in vitro and in vivo models 




Model Liver injury/disease CeO2NPs 
(size, dose, and 
administration route) 
Reference 
In vitro HepG2 cells 
(human hepatic cells) 
Oxidative stress (H2O2) 4 nm; 100 µg/ml 
[37a] 
In vitro HepG2 cells 
(human hepatic cells) 
Hyperglycemia 8.5 µg/ml [96] 
In vitro RAW264.7 cells 
(murine macrophages) 
Lipopolysaccharide 4-5 nm; 5-1000 µg/ml [97] 




1.9 nm; 5-200 µmol/L [98] 
In vitro Primary portal endothelial 
cells 
Cirrhotic rats 4 nm; 1 µg/ml [18c] 
In vitro HepG2 cells 
(human hepatic cells) 
Steatosis 4nm; 10 µg/ml [79] 
In vivo Sprague Dawley rats Hepatotoxicity (Monocrotaline) 25 nm; 0.01 µg/kg; i.p. [107] 
In vivo BALB/c-mice Hepatotoxicity (CCl4) 3-5 nm; 0.5 mg/kg; i.p. 
[15a, 72] 
In vivo Albino Wistar rats Hepatotoxicity 
(D-galactosamine and 
lipopolysaccharide) 
25 nm; 0.01 µg/kg; i.p. [105a] 
In vivo Sprague Dawley rats Peritonitis (polymicrobial) 10-30 nm; 0.5 mg/kg; i.v. [109] 
In vivo Wistar rats Liver fibrosis (CCl4) 4-20 nm; 0.1 mg/kg; i.v. 
[37a] 
In vivo Wistar rats Cirrhosis (CCl4) 4 nm; 0.1 mg/kg: i.v. 
[18c] 
In vivo Wistar rats Non alcoholic fatty liver disease (MCD 
diet) 
4 nm; 0.1 mg/kg; i.v. [110] 
In vivo Wistar rats Liver regeneration (acetaminophen) 4 nm; 0.1 mg/kg; i.v [111] 
In vivo Wistar rats Liver regeneration (hepatectomy) 4 nm; 0.1 mg/kg; i.v [112] 
In vivo Wistar rats Non alcoholic fatty liver disease 
(Neonatal monosodium glutamate) 
1-5 nm; 1 mg/kg; oral [113] 
In vivo Sprague Dawley rats Hepatic ischemia reperfusion injury 10-30 nm;0.5 mg/kg; i.v. [109] 
In vivo Sprague Dawley rats Sepsis (Lipopolysaccharide) 4-5 nm; 0.5 mg/kg; i.v [97] 
In vivo Sprague Dawley rats Hepatotoxicity 
(Doxorubicin) 
100 nm; 0.5 mg/kg; i.p. [105b] 
In vivo BALB/c-mice Hepatocellular carcinoma (DEN) <10 nm; 100-200 µg/kg; i.p. [37b] 








Table 3. Summary of the advantages of CeO2NPs respect classic antioxidants. 
Classic antioxidants CeO2NPs 
No targeted activity. It can be functionalized, controlled biodistribution. 
Limited activity: often scavenge one free radical. Multienzymatic: catalase-like, SOD-like, peroxidase-like 
activities, NO scavenging, etc. and can participate in the 
multiplicity of cross-reactions between ROS and 
inflammation. 
Limited activity: they are metabolized; after reaction 
become inactivated. 
Not entirely consumed during reaction and thus can work 
at low doses. 
Limited activity: short half-life. Long residence time in tissue. 
No controlled activity (they become inactivated after 
reaction). 
ROS buffers: only act in conditions of ROS overproduction. 
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Cerium Oxide Nanoparticles: Advances in Biodistribution,  
Toxicity and Preclinical Exploration 
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The burgeoning potential of antioxidant nanoparticles in theranostic applications faces 
apparently contradictory reports of either medical benefits or toxicity. This delays translation 
to clinical practice. Sources of those discrepancies are summarized focusing on the 
paradigmatic case of cerium oxide in liver disease. This analysis contributes to overcoming 
similar discrepancies of other nanoparticles and will enable the design of improved 
nanomedicines. 
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